Alnylam Pharmaceuticals Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has ranked first in Boston Globes 2021 Top Places to Work in the Largest Employer category. This is the seventh consecutive year that Alnylam has been named a Top Place to Work by the Boston Globe and the first year that Alnylam has been eligible for the Largest Employer category (> 1,000 employees). Companies named to the Top Places to Work list are c

Exchange Traded Concepts LLC decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,091 shares of the biopharmaceutical companys stock after selling 1,997 shares during the period. Exchange Traded Concepts LLCs holdings []

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) shares, rose in value on Friday, 11/26/21, with the stock price down by -0.14% to the previous days close as strong demand from buyers drove the stock to $188.53. Actively observing the price movement in the last trading, the stock closed the session at $188.80, falling within a range of $185.65 What Analysts Were Expecting After Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell -0.14% Read More »

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective upped by Needham & Company LLC from $180.00 to $205.00 in a research note issued to investors on Monday morning, The Fly reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on the stock. HC Wainwright […]

The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a neutral rating to a buy rating in a research note published on Monday, PriceTargets.com reports. The firm currently has $273.00 price objective on the biopharmaceutical companys stock. A number of other equities research analysts have also weighed in on ALNY. Barclays boosted their []

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Heron Therapeutics (NASDAQ:HRTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability. Valuation & Earnings This table compares Alnylam Pharmaceuticals and Heron Therapeutics top-line revenue, earnings per share []

The shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have received a price target of $205 from Needham. These are the details.

Arrowhead and Alnylam up by 8% each Related Stocks: NVO , DRNA , LLY , MRK , ALNY , ARWR , NVS , ALXN , RHHBY ,

RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) to Outperform from Sector Perform with a price target of $225, up from $144. While M&A optionality is "nice" to have, analyst Luca Issi''s call is fundamental. According to Issi, the stock may be viewed as expensive at a $21 billion market cap and 30x sales, but this is a great entry point at a 15% discount from October highs and ahead of key catalysts that can unlock value in the short-term and on the heels of an "impressive" R&D Day. Related Full story available on Benzinga.com

Alnylam stock popped to a month high Monday after the company at its research and development day unveiled "a catalyst-rich calendar" for 2022.

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ: ALNY ) has observed the following analyst ratings:

RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M&A optionality is "nice" to have, analyst L

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by investment analysts at Royal Bank of Canada from a sector perform rating to an outperform rating in a report released on Monday, The Fly reports. The brokerage currently has a $225.00 price objective on the biopharmaceutical companys stock, up from their previous price objective of $144.00. Royal Bank of []

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned a consensus rating of Buy from the fifteen research firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokerages []